| Revision as of 15:31, 6 December 2011 editBeetstra (talk | contribs)Edit filter managers, Administrators172,055 edits Saving copy of the {{drugbox}} taken from revid 460514656 of page Sodium_cellulose_phosphate for the Chem/Drugbox validation project (updated: ''). |
Latest revision as of 18:37, 24 June 2024 edit Boghog (talk | contribs)Autopatrolled, Extended confirmed users, IP block exemptions, New page reviewers, Pending changes reviewers, Rollbackers, Template editors137,879 edits consistent citation formatting |
| Line 1: |
Line 1: |
|
|
{{cs1 config|name-list-style=vanc|display-authors=6}} |
|
{{ambox | text = This page contains a copy of the infobox ({{tl|drugbox}}) taken from revid of page ] with values updated to verified values.}} |
|
|
{{Drugbox |
|
{{Drugbox |
|
⚫ |
| verifiedrevid = 464400440 |
|
| Verifiedfields = changed |
|
|
⚫ |
<!-- Clinical data --> |
| ⚫ |
| verifiedrevid = 402053217 |
|
|
|
|
| ⚫ |
<!--Clinical data--> |
|
|
| tradename = |
|
| tradename = |
|
| Drugs.com = {{drugs.com|CONS|sodium_cellulose_phosphate}} |
|
| Drugs.com = {{drugs.com|CONS|sodium_cellulose_phosphate}} |
|
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
|
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
|
| pregnancy_US = <!-- A / B / C / D / X --> |
|
| pregnancy_US = <!-- A / B / C / D / X --> |
|
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--> |
|
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled --> |
|
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII --> |
|
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII --> |
|
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C --> |
|
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C --> |
|
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
|
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
|
⚫ |
<!-- Identifiers --> |
|
|
|
| ⚫ |
<!--Identifiers--> |
|
|
| ATC_prefix = V03 |
|
| ATC_prefix = V03 |
|
| ATC_suffix = AG01 |
|
| ATC_suffix = AG01 |
|
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
|
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
|
| ChemSpiderID = NA |
|
| ChemSpiderID = none |
|
⚫ |
<!-- Chemical data --> |
|
|
|
| ⚫ |
<!--Chemical data--> |
|
|
}} |
|
}} |
|
|
'''Sodium cellulose phosphate''' is a drug used to treat ] and ]. It has been investigating for the prevention of ],<ref name="urlSodium Cellulose Phosphate (Oral Route) - MayoClinic.com">{{cite web|url=http://www.mayoclinic.com/health/drug-information/DR600321 |title=Sodium Cellulose Phosphate (Oral Route) |format= |website= MayoClinic.com|access-date=2009-02-01}}</ref><ref name="pmid3896714">{{cite journal | vauthors = Lake KD, Brown DC | title = New drug therapy for kidney stones: a review of cellulose sodium phosphate, acetohydroxamic acid, and potassium citrate | journal = Drug Intelligence & Clinical Pharmacy | volume = 19 | issue = 7–8 | pages = 530–539 | year = 1985 | pmid = 3896714 | doi = 10.1177/106002808501900705 | s2cid = 28348806 }}</ref> but with limited efficacy.<ref>{{cite journal | vauthors = Backman U, Danielson BG, Johansson G, Ljunghall S, Wikström B | title = Treatment of recurrent calcium stone formation with cellulose phosphate | journal = The Journal of Urology | volume = 123 | issue = 1 | pages = 9–13 | date = January 1980 | pmid = 7351731 | doi = 10.1016/s0022-5347(17)55749-3 }}</ref> |
|
|
|
|
|
This compound is an ion-exchange resin that can not be absorbed by the body. However, it can be used to restore the normal intestinal calcium absorption. When it is taken orally, it binds strongly to calcium and inhibits its absorption into the blood. From there, inhibition is caused due to the lower intraluminal calcium levels, which is typically available for absorption.<ref name="Pak_1983">{{cite journal | vauthors = Pak CY, Nicar MJ, Britton F | s2cid=45157990 | title=Clinical Experience with Sodium Cellulose Phosphate | journal=World Journal of Urology | volume=1 | issue=3 | year=1983 | pages=1–2 | doi=10.1007/BF00326909 }}</ref> |
|
|
|
|
|
The mechanism of action of the drug compound can cause a couple of internal effects. Due to the binding activity of the compound with calcium, it will also bind with magnesium and cause a depletion in the body. Working off of this effect, sodium cellulose phosphate will bind with divalent intestinal cations. Because of this binding, more oxalate is available in the blood. This high level of oxalate within the intestine can also be a source of renal stones. |
|
|
|
|
|
== Medical uses == |
|
|
|
|
|
=== Hypercalcemia === |
|
|
] occurs when there is a raised level of ] in the ], compared to the normal range of 2.2–2.6 mmol/L. Typical symptoms of this condition include renal stones, bone pain, abdominal discomfort, and nausea/vomiting. More severe symptoms are associated with psychiatric overtones which are consumed with anxiety, depression, and insomnia. |
|
|
|
|
|
=== Hypercalciuria === |
|
|
] occurs when there is an elevated level of ]. This condition is due to severe ] within the intestines. |
|
|
|
|
|
=== Available forms === |
|
|
The major US ] of sodium cellulose phosphate is '''Calcibind''', which was developed and brought to market by Mission Pharma. Calcibind is a powder dosage form, which comes in small, 2.5 gram doses, individually packaged. The ] for this product was approved on December 28, 1982. The product was eventually removed from the market for reasons that have not been found at this time. |
|
|
|
|
|
== Research == |
|
|
In the late 1970s and early 1980s, physiological action studies took place to show how intestinal calcium was absorbed and how it affects other functions within the body. By a study done at the University of Texas, it was found that sodium cellulose phosphate inhibited calcium absorption through three separate techniques: |
|
|
* Calcium balance studies |
|
|
* External counting method |
|
|
* Formal kinetic analysis |
|
|
|
|
|
Through these studies, major conclusions were made regarding the drug compound. Sodium cellulose phosphate reduces the renal excretion of magnesium and calcium. Phosphate and oxalate were both increased in the urine, one due to intestinal hydrolysis and the other to a reduced oxalate complex. Overall, it was noted that the drug could be used to correct the increased calcium absorption that occurs in absorptive hypercalciuria.<ref name="Pak_1983"/> |
|
|
|
|
|
== References == |
|
|
{{Reflist}} |
|
|
|
|
|
{{Other therapeutic products}} |
|
|
|
|
|
] |
|
|
|
|
|
{{Pharmacology-stub}} |